Article
Medicine, General & Internal
Nicolas Bertrand, Pierre Guerreschi, Nicole Basset-Seguin, Philippe Saiag, Alain Dupuy, Sophie Dalac-Rat, Veronique Dziwniel, Cesar Depoortere, Alain Duhamel, Laurent Mortier
Summary: Neoadjuvant vismodegib treatment reduces the risk of surgery for patients with locally advanced basal cell carcinoma, minimizing the functional and aesthetic consequences of surgery.
Article
Dermatology
Veronica Ruiz-Salas, Sebastian Podlipnik, Alejandra Sandoval-Clavijo, Onofre Sanmartin-Jimenez, Eduardo Bernia-Petit, Montserrat Bonfill-Orti, Patricia Bassas-Freixas, Mireia Yebenes-Marsal, Angeles Florez-Menendez, Joaquim Sola-Ortigosa, Miquel Just-Sarobe, Rafael S. Aguayo-Ortiz, Emili Masferrer i Niubo, Monica Quintana-Codina, Gustavo Deza, Ane Jaka, Maria Jose Fuentes, Javier Canueto, Agusti Toll
Summary: This study analyzed the therapeutic management and evolution of relapses and lack of response in patients with locally advanced and/or multiple basal cell carcinomas who received vismodegib in a real-life multicentre setting. The results showed that vismodegib is effective in routine clinical practice, with a low risk of recurrence after achieving complete response and feasible rechallenge with vismodegib, which resulted in a good response in most patients.
Article
Ophthalmology
Assaf Gershoni, Alon Tiosano, Meydan Ben Ishai, Edward Barayev, Guy J. Ben Simon, Iftach Yassur
Summary: The study evaluated the impact of locally advanced periocular basal cell carcinoma (POLA-BCC) on health-related quality of life (HRQoL) and the efficacy of vismodegib treatment. Results showed that patients with POLA-BCC had significantly impaired overall functioning at baseline, but demonstrated significant improvement at the last follow-up.
Article
Dermatology
Helene Marescassier, Lea Dousset, Marie Beylot-Barry, Philippe Celerier, Loic Vaillant, Christophe Bedane, Franck Leclere, Ewa Wierzbicka-Hainaut, Marie Masson Regnault
Summary: In a retrospective multicenter study, factors associated with non-response to vismodegib in patients with locally advanced basal cell carcinomas (laBCC) were identified. Muscle involvement, history of radiotherapy, and intermittent use of vismodegib were significantly associated with non-response. Further studies are needed to confirm these findings due to the limited sample size.
Article
Oncology
Laura Eibenschutz, Silvia Caputo, Emanuela Camera, Anna Carbone, Vitaliano Silipo, Emilia Migliano, Caterina Aurizi, Carlo Cota, Pasquale Frascione, Barbara Bellei
Summary: Nevoid basal cell carcinoma syndrome (NBCCS) is a genetic disorder that predisposes individuals to basal cell carcinoma (BCC) due to mutations in genes related to the Hedgehog (Hh) pathway. Somatic mutations in this pathway are associated with sporadic BCC, and targeting this pathway with drugs like vismodegib and sonidegib could potentially be a therapeutic option. These drugs impact fibroblast functions supporting tumor growth and could be considered for BCC therapy regardless of the mutation status of Hh components in neoplastic cells.
Article
Dermatology
Mustafa Gurbuz, Izzet Dogan, Erman Akkus, Hande Ermis, Gungor Utkan, Sezai Vatansever, Faruk Tas
Summary: The study evaluated the efficacy of vismodegib treatment in locally advanced and metastatic basal cell carcinoma, showing it was well tolerated and effective in real-world settings. Treatment responses were most commonly seen within 2 months of initiation, with chemotherapy post-vismodegib showing significant improvement in overall survival compared to no treatment or surgery. The most common adverse events included fatigue, muscle spasms, alopecia, and weight loss.
DERMATOLOGIC THERAPY
(2021)
Article
Oncology
Diya M. Sabu, Jeska Kroes, Charles Gilham, Ann Fleming, Fergal C. Kelleher
Summary: Basal cell carcinomas are common in Caucasian populations, with the Hedgehog pathway playing a significant role in their development. This case highlights the dramatic response of an elderly patient with untreated sporadic Basal cell carcinoma to the Hedgehog pathway inhibitor Vismodegib, enabling definitive treatment to be pursued.
CURRENT PROBLEMS IN CANCER
(2021)
Article
Dermatology
Tanja Mesti, Masa Sever, Janja Ocvirk
Summary: Vismodegib has demonstrated significant efficacy in the treatment of laBCC, multiple BCC, and G-G Syn patients in Slovenia, achieving disease control rates of 95% to 100%.
Article
Dermatology
Alessia Villani, Gabriella Fabbrocini, Claudia Costa, Massimiliano Scalvenzi
Summary: This study discusses a case of locally advanced basal cell carcinoma successfully treated with vismodegib, highlighting the importance of using dermoscopy and reflectance confocal microscopy in detecting subclinical recurrent basal cell carcinoma during treatment.
DERMATOLOGY AND THERAPY
(2021)
Article
Oncology
Raquel Wescott, Wolfram Samlowski
Summary: Treatment with vismodegib or sonidegib can effectively reduce the number of new basal cell carcinomas in patients with nevoid basal-cell carcinoma syndrome (Gorlin syndrome) and suppress the progression of existing tumors.
Article
Dermatology
Ralf Gutzmer, Carmen Loquai, Caroline Robert, Brigitte Dreno, Alexander Guminski, Karl Lewis, Ramon Arntz, Serena Martelli, Nicholas Squittieri, Meenal Kheterpal
Summary: This analysis compared the incidence and onset of adverse events in patients treated with sonidegib and vismodegib for basal cell carcinoma. Sonidegib-treated patients experienced lower incidence and delayed onset of adverse events compared to those treated with vismodegib.
DERMATOLOGY AND THERAPY
(2021)
Article
Dermatology
Shane D. B. Smith, Callisia N. Clarke, Melanie A. Clark, Amy K. Harker-Murray, Olayemi Sokumbi
Summary: Basal cell carcinoma is the most commonly diagnosed cutaneous cancer in the United States, with about 90% of patients having a mutation in the hedgehog-signaling pathway. Most patients have an excellent prognosis with surgical treatment, but some may experience cosmetic or functional impairment. Vismodegib, a hedgehog pathway inhibitor, has shown success in treating locally advanced BCC patients.
AMERICAN JOURNAL OF DERMATOPATHOLOGY
(2021)
Article
Oncology
Taku Kimura, Ken-ichiro Sakata, Jun Sato, Chisato Ouchi, Noritaka Ohga, Aya Yanagawa-Matsuda, Kyoko Hida, Yoshimasa Kitagawa
Summary: Metastatic basal cell carcinoma poses challenges in current treatment and requires consideration of treatment history and pathohistological features in posttreatment planning.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Dermatology
Justin Tong, Brandon Mitchell, Kathryn Roth, Diane Logan, Scott Ernst
Summary: This study aimed to explore the efficacy of vismodegib in treating advanced basal cell carcinoma, with half of the patients achieving complete response and a significant number becoming eligible for surgery or radiotherapy. However, treatment-related adverse effects remained a important limiting factor in treatment duration.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
(2022)
Article
Ophthalmology
Alon Tiosano, Meydan Ben-Ishai, Eyal Fenig, Guy J. Ben Simon, Iftach Yassur
Summary: This study established a model to predict the treatment outcome of PERIOCULAR LOCALLY ADVANCED BASAL CELL CARCINOMA (POLA BCC) based on the initial response to vismodegib treatment. The model showed high predictive accuracy for complete response (CR) based on the reduction in tumor size at 3 and 6 months of treatment. These findings provide valuable insights for treatment management decisions in patients with POLA BCC.
Article
Dermatology
Christine L. Monteleon, Andrew McNeal, Elizabeth K. Duperret, Seung J. Oh, Emily Schapira, Todd W. Ridky
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2015)
Article
Oncology
Andrew S. McNeal, Kevin Liu, Vihang Nakhate, Christopher A. Natale, Elizabeth K. Duperret, Brian C. Capell, Tzvete Dentchev, Shelley L. Berger, Meenhard Herlyn, John T. Seykora, Todd W. Ridky
Article
Biology
Christopher A. Natale, Elizabeth K. Duperret, Junqian Zhang, Rochelle Sadeghi, Ankit Dahal, Kevin Tyler O'Brien, Rosa Cookson, Jeffrey D. Winkler, Todd W. Ridky
Article
Biology
Christopher A. Natale, Jinyang Li, Junqian Zhang, Ankit Dahal, Tzvete Dentchev, Ben Z. Stanger, Todd W. Ridky
Editorial Material
Oncology
Elizabeth K. Duperret, Todd W. Ridky
CANCER BIOLOGY & THERAPY
(2014)
Review
Cell Biology
Elizabeth K. Duperret, Todd W. Ridky
Article
Cell Biology
Elizabeth K. Duperret, Seung Ja Oh, Andrew McNeal, Stephen M. Prouty, Todd W. Ridky
Editorial Material
Cell & Tissue Engineering
Todd W. Ridky, Paul A. Khavari
Review
Medicine, Research & Experimental
Vladimir Ratushny, Michael D. Gober, Ryan Hick, Todd W. Ridky, John T. Seykora
JOURNAL OF CLINICAL INVESTIGATION
(2012)
Article
Biochemistry & Molecular Biology
Todd W. Ridky, Jennifer M. Chow, David J. Wong, Paul A. Khavari
Letter
Dermatology
Christine L. Monteleon, In Young Lee, Todd W. Ridky
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2019)
Article
Gastroenterology & Hepatology
Christopher A. Natale, Jinyang Li, Jason R. Pitarresi, Robert J. Norgard, Tzvete Dentchev, Brian C. Capell, John T. Seykora, Ben Z. Stanger, Todd W. Ridky
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2020)
Article
Oncology
Cristina Aguirre-Portoles, Riley Payne, Aspen Trautz, J. Kevin Foskett, Christopher A. Natale, John T. Seykora, Todd W. Ridky
Summary: Testosterone signaling through ZIP9 mediates some of the sex differences in melanoma, and drugs that target AR can be repurposed to block ZIP9 and inhibit melanoma in males.
Article
Multidisciplinary Sciences
Jaskaren Kohli, Chen Ge, Eleni Fitsiou, Miriam Doepner, Simone M. Brandenburg, William J. Faller, Todd W. Ridky, Marco Demaria
Summary: Research shows that senescent melanocytes in culture and nevi express high levels of the anti-apoptotic protein BCL-W, but remain insensitive to the pan-BCL-2 inhibitor ABT-263. Resistance to ABT-263 is driven by mTOR-mediated enhanced translation of another anti-apoptotic protein, MCL-1. The combination of ABT-263 and MCL-1 inhibitors results in synthetic lethality to senescent melanocytes, with topical application sufficient to eliminate nevi.
NATURE COMMUNICATIONS
(2022)
